Recent reports have identified CD44 as a potential marker for the identification of cancer stem cells in ovarian cancer, and confirmed the functionality of the TLR4-MyD88 pathway in only the CD44+ cell population [25,26]. This evidence concerns the gene TLR4 and ovarian carcinoma.